These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11855871

  • 1. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A, Crespo C, García-López JL, Pedraza M, Garrido P, Lastra E, Moyano A.
    Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Mar; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 3. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P, GONO (Italian Gruppo Oncologico del Nord-Ovest).
    Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT.
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
    Sørensen P, Høyer M, Jakobsen A, Malmström H, Havsteen H, Bertelsen K.
    Gynecol Oncol; 2001 Apr; 81(1):58-62. PubMed ID: 11277650
    [Abstract] [Full Text] [Related]

  • 7. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA.
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [Abstract] [Full Text] [Related]

  • 8. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
    Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C.
    Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH, Elias A, Ryan L.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK.
    Cancer; 2002 Jul 15; 95(2):322-30. PubMed ID: 12124833
    [Abstract] [Full Text] [Related]

  • 11. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, Homesley HD, Malfetano JH.
    Gynecol Oncol; 1994 Apr 15; 53(1):24-6. PubMed ID: 8175017
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
    Markman M, Spriggs D, Burger RA, Carson LF, Lentz SS, Gallion H.
    Gynecol Oncol; 2001 Mar 15; 80(3):359-63. PubMed ID: 11263932
    [Abstract] [Full Text] [Related]

  • 13. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan 15; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S, O'byrne KJ.
    Gynecol Oncol; 2004 Aug 15; 94(2):502-8. PubMed ID: 15297195
    [Abstract] [Full Text] [Related]

  • 15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 15; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS, Judson PL, Argenta PA, Carson LF, Boente MP.
    Gynecol Oncol; 2004 Nov 15; 95(2):347-51. PubMed ID: 15491756
    [Abstract] [Full Text] [Related]

  • 17. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1989 Feb 15; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
    Li XP, Cui H, Zhou JW, Wei LH, Wang JL, Zhao Y, Wang Y, Wang SJ, Zhu HL, Dong L, Zhang H.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct 15; 43(10):724-7. PubMed ID: 19087535
    [Abstract] [Full Text] [Related]

  • 19. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
    Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, Nam JH, Kang SB, Lee KH, Song YS.
    Gynecol Oncol; 2008 Jun 15; 109(3):359-63. PubMed ID: 18405948
    [Abstract] [Full Text] [Related]

  • 20. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
    Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 1998 Aug 15; 70(2):272-4. PubMed ID: 9740704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.